– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing med ...

BOULDER, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the first quarter and ended March 31, 2025. Highlights: Fifth consecutive quarter of double digit increases in revenue (12% year over-year-growth in Q1)Gross profit increased 15% and EPS improved 20% year over yearContinued positive operating and free cash flow generation "As planned, we continued to deliver on positive free cash flow and double-digit growth for ...

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and granted an aggregate of 101,800 restricted stock unit (“RSU”) awards to 35 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 In ...

Company to Provide Corporate Updates Including New Developments, First Quarter 2025 Overview and Financial Results; Conference Call to be Held Wednesday, May 14, 2025, at 4:30 P.M. Eastern TimeMIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive advanced and smart home platform technology company for homes and buildings, with more than 97 issued and pending patents globally and a portfolio of over 60 lighting and home décor websites, announces today th ...

New Customer Launches Drive 40% Revenue Growth for Software Subscriptions and Services Strong Balance Sheet of $109.7 Million Powering R&D Activities in AI-Driven Customer Platform and Corporate Initiatives AUSTIN, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), a leader in enterprise cloud solutions for mobile applications, today reported financial results for the first quarter ended March 31, 2025. Financial Highlights Software subscriptions and service ...

Annualized recurring revenue (“ARR”) of $837 million, an increase of 4% year-over-yearTotal revenue of $210 million, up 3% year-over-year; Product subscriptions revenue of $204 million, up 4% year-over-yearGAAP operating loss of $0.1 million; Non-GAAP operating income of $32 millionNet cash provided by operating activities of $30 million; Free cash flow of $25 million BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Rapid7, Inc. (Nasdaq: RPD), a leader in extended risk and threat detection, today announced its fina ...

Core Insights - Bolt Biotherapeutics reported financial results for Q1 2025, highlighting advancements in their immunotherapy pipeline and a cash balance of $58 million to fund operations through mid-2026 [1][4][10]. Business Update - The company is advancing its pipeline of novel immunotherapies, with promising early clinical data for BDC-3042 presented at AACR 2025 and the opening of enrollment for BDC-4182 [2][4]. - BDC-3042, a proprietary agonist antibody targeting dectin-2, showed a favorable safety profile and anti-tumor activity in a Phase 1 study for patients with metastatic solid tumors [5]. - BDC-4182, targeting claudin 18.2, has opened for enrollment and demonstrated complete regressions in preclinical models [5]. Financial Performance - Collaboration revenue decreased to $1.2 million in Q1 2025 from $5.3 million in Q1 2024, primarily due to the completion of performance obligations under a previous agreement [10]. - Research and Development (R&D) expenses were $9.5 million in Q1 2025, down from $16.5 million in Q1 2024, attributed to reduced clinical expenses and restructuring [10]. - General and Administrative (G&A) expenses also decreased to $3.8 million from $5.8 million year-over-year [10]. - The net loss for Q1 2025 was $11.0 million, compared to a net loss of $10.8 million in Q1 2024 [12]. Cash Position - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $58 million, expected to support operations through mid-2026 [4][10].

MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. “Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in ...

CARLSBAD, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Viasat, Inc. (NASDAQ: VSAT), a global leader in satellite communications, today announced the appointments of Dr. William “Bill” LaPlante and Michael Paull to its Board of Directors, effective immediately. “We are delighted that Dr. LaPlante and Mr. Paull have agreed to join our Board,” said Mark Dankberg, Chairman of the Board and CEO at Viasat. “Dr. LaPlante brings a wealth of defense and national security experience, while Mr. Paull is a proven leader in ...

Dr. Sailesh Chittipeddi New Addition to the Lantronix Board of Directors IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced that Sailesh Chittipeddi, Ph.D., has joined the Lantronix Board of Directors as an independent director, effective May 6, 2025. Following the appointment of Chittipeddi, the Lantronix Board of Directors will be comprised of five directors, four o ...